Markets:

Overview

News

Currencies

International

Treasuries

Paratek Pharmaceuticals, Inc. - Common Stock (NQ:PRTK)

N/A UNCHANGED

Last Price Updated: 4:00 PM EDT, Sep 20, 2023 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Paratek Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 Next >

Earnings Outlook For Paratek Pharmaceuticals ↗

May 03, 2022

Paratek Pharmaceuticals (NASDAQ:PRTK) is set to give its latest quarterly earnings report on Wednesday, 2022-05-04. Here's what investors need to know before the announcement. Analysts estimate that...

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

March 16, 2022

On Wednesday, 90 companies set new 52-week lows. Areas of Significance In Today's 52-Week Lows: The company with the largest market cap to set a new 52-week low was...

Via Benzinga

Stocks That Hit 52-Week Lows On Monday ↗

March 28, 2022

On Monday, 147 stocks hit new 52-week lows. Areas of Significance In Today's 52-Week Lows: The largest company by market cap to set a new 52-week low was...

Via Benzinga

Paratek Pharmaceuticals: Q4 Earnings Insights ↗

March 14, 2022

Paratek Pharmaceuticals (NASDAQ:PRTK) reported its Q4 earnings results on Monday, March 14, 2022 at 07:30 AM. Here's what investors need to know about the announcement...

Via Benzinga

Earnings Scheduled For March 14, 2022 ↗

March 14, 2022

Companies Reporting Before The Bell • F45 Training Holdings (NYSE:FXLV) is projected to report earnings for its fourth quarter. • The One Group Hospitality (...

Via Benzinga

Paratek Pharmaceuticals's Earnings: A Preview ↗

March 11, 2022

Paratek Pharmaceuticals (NASDAQ:PRTK) is set to give its latest quarterly earnings report on Monday, 2022-03-14. Here's what investors need to know before the announcement....

Via Benzinga

The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings ↗

March 13, 2022

Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments...

Via Benzinga

The Daily Biotech Pulse: Pfizer Begins Late-Stage Pediatric COVID Pill Study, Midatech And J&J Unit Expand R&D Collaboration, AbbVie-Alvotech Settle Humira Dispute ↗

March 09, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus AbbVie Settles With Alvotech On Humira Biosimilar Patent Dispute AbbVie, Inc...

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

February 18, 2022

Gainers Biofrontera (NASDAQ:BFRA) stock moved upwards by 11.8% to $3.49 during Friday's pre-market session. The market value of their outstanding shares is at $98.9...

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

February 17, 2022

Gainers NeuroOne Medical Tech (NASDAQ:NMTC) shares moved upwards by 12.3% to $3.0 during Thursday's pre-market session. The company's market cap stands at $48.5...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For February 10, 2022 ↗

February 10, 2022

Upgrades According to Gordon Haskett, the prior rating for Williams-Sonoma Inc (NYSE:WSM) was changed from Hold to Accumulate. Williams-Sonoma earned $3.32 in the third quarter,...

Via Benzinga

Week In Review: BeiGene Completes $3.5 Billion IPO On Shanghai STAR Board ↗

December 18, 2021

BeiGene, a Beijing oncology company, began trading on the Shanghai STAR Board as the last step in its $3.5 billion IPO. The company is now listed in the US, Hong Kong, and Shanghai.

Via Talk Markets

Zai Lab's Nuzyra Approved In China For Bacterial Infections ↗

December 16, 2021

The China National Medical Products Administration (NMPA) has approved Zai Lab Limited's (NASDAQ: ZLAB) Nuzyra (omadacycline), a novel antibiotic with both oral...

Via Benzinga

Recap: Paratek Pharmaceuticals Q3 Earnings ↗

November 08, 2021

Paratek Pharmaceuticals (NASDAQ:PRTK) reported its Q3 earnings results on Monday, November 8, 2021 at 04:05 PM. Here's what investors need to know about the announcement....

Via Benzinga

Paratek Pharmaceuticals's Return On Capital Employed Insights ↗

November 08, 2021

According to Benzinga Pro, during Q2, Paratek Pharmaceuticals (NASDAQ:PRTK) earned $14.09 million, a 199.07% increase from the preceding quarter. Paratek Pharmaceuticals also...

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

October 18, 2021

Gainers Dermata Therapeutics (NASDAQ:DRMA

Via Benzinga

Earnings Scheduled For November 8, 2021 ↗

November 08, 2021

Companies Reporting Before The Bell • Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $0.11 per share on revenue of $215.14 million. •...

Via Benzinga

Paratek Secures BARDA Funding To Develop Nuzyra Antibiotic For Pulmonary Anthrax ↗

September 28, 2021

The Biomedical Advanced Research and Development Authority (BARDA) has awarded an option under Paratek Pharmaceuticals Inc's (NASDAQ: PRTK) Project...

Via Benzinga

The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK Subsidiary To Develop Long-Acting HIV Preventive ↗

September 28, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 27) Acceleron Pharma Inc. (...

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

September 27, 2021

Gainers Paratek Pharmaceuticals (NASDAQ:PRTK...

Via Benzinga

48 Biggest Movers From Friday ↗

September 27, 2021

Gainers ZIVO Bioscience, Inc. (NASDAQ: ZIVO) shares climbed 58% to close at $5.45 on Friday. Clearwater Analytics Holdings, Inc. (NYSE: CWAN) surged 40.9% to settle at $25.37...

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

September 24, 2021

Gainers Molecular Templates (NASDAQ:MTEM) stock rose 14.13% to $7.59 during Friday's regular session. Trading volume for Molecular Templates's stock is 937.9K as...

Via Benzinga

34 Stocks Moving In Friday's Mid-Day Session ↗

September 24, 2021

Gainers ZIVO Bioscience, Inc. (NASDAQ: ZIVO) shares jumped 76.2% to $6.08. Unique Fabricating, Inc. (NASDAQ: UFAB) jumped 37.7% to $3.47. Form 4 filings from late Thursday...

Via Benzinga

How Good Are Paratek Pharmaceuticals's Earnings? | Return On Capital Employed ↗

September 17, 2021

According to Benzinga Pro, during Q2, Paratek Pharmaceuticals (NASDAQ:PRTK) earned $14.09 million, a 199.07% increase from the preceding quarter. Paratek Pharmaceuticals also...

Via Benzinga

The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck ↗

August 19, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 18) AbbVie Inc. (NYSE: ABBV)...

Via Benzinga

Paratek's Antibiotic Gets FDA Orphan Drug Tag For Lung Infection ↗

August 19, 2021

The FDA has granted Orphan Drug Designation to Paratek Pharmaceuticals Inc's (NASDAQ: PRTK), Nuzyra (omadacycline) for infections caused by Nontuberculous...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

August 18, 2021

Gainers Protagenic Therapeutics (NASDAQ:PTIX...

Via Benzinga

Paratek Pharmaceuticals (PRTK) Q2 2021 Earnings Call Transcript ↗

August 10, 2021

PRTK earnings call for the period ending June 30, 2021.

Via The Motley Fool

Topics Earnings

Paratek Pharmaceuticals: Q2 Earnings Insights ↗

August 09, 2021

Shares of Paratek Pharmaceuticals (NASDAQ:PRTK) rose in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share increased 137.74%...

Via Benzinga

Earnings Scheduled For August 9, 2021 ↗

August 09, 2021

Companies Reporting Before The Bell • Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $1.57 per share on revenue of $215.17 million. •...

Via Benzinga

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.